• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Arsenic trioxide for reprogramming the bone marrow microenvironment to eliminate acute myeloid leukemia blasts.

作者信息

Kegyes David, Teodorescu Patric, Supeanu Teodora, Nagai Yuya, Zhong Guo, Mathews Vikram, Isoherranen Nina, Ghiaur Gabriel

机构信息

Sidney Kimmel Cancer Center Johns Hopkins University Baltimore Maryland USA.

MedFUTURE Research Center for Advanced Medicine Cluj-Napoca Romania.

出版信息

Hemasphere. 2025 Aug 11;9(8):e70191. doi: 10.1002/hem3.70191. eCollection 2025 Aug.

DOI:10.1002/hem3.70191
PMID:40791735
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12336997/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b8/12336997/ce2f32ba71c3/HEM3-9-e70191-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b8/12336997/b4476f3c6916/HEM3-9-e70191-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b8/12336997/ce2f32ba71c3/HEM3-9-e70191-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b8/12336997/b4476f3c6916/HEM3-9-e70191-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b8/12336997/ce2f32ba71c3/HEM3-9-e70191-g002.jpg

相似文献

1
Arsenic trioxide for reprogramming the bone marrow microenvironment to eliminate acute myeloid leukemia blasts.三氧化二砷用于重编程骨髓微环境以清除急性髓系白血病母细胞。
Hemasphere. 2025 Aug 11;9(8):e70191. doi: 10.1002/hem3.70191. eCollection 2025 Aug.
2
Dual oligopeptides modification mediates arsenic trioxide containing nanoparticles to eliminate primitive chronic myeloid leukemia cells inside bone marrow niches.双寡肽修饰介导三氧化二砷纳米颗粒消除骨髓龛内原始慢性髓系白血病细胞。
Int J Pharm. 2020 Apr 15;579:119179. doi: 10.1016/j.ijpharm.2020.119179. Epub 2020 Feb 26.
3
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.高剂量抗坏血酸盐和三氧化二砷在体外可选择性杀死急性髓性白血病和急性早幼粒细胞白血病的母细胞。
Oncotarget. 2017 May 16;8(20):32550-32565. doi: 10.18632/oncotarget.15925.
4
Curcumin combined with arsenic trioxide enhances autophagy and immune surveillance to inhibit immune escape in acute myeloid leukemia.姜黄素联合三氧化二砷可增强自噬和免疫监视，以抑制急性髓系白血病的免疫逃逸。
Int Immunopharmacol. 2025 May 28;159:114966. doi: 10.1016/j.intimp.2025.114966.
5
Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia.一名急性早幼粒细胞白血病全反式维甲酸耐药复发患者使用三氧化二砷治疗成功。
Ann Hematol. 1999 Jul;78(7):329-32. doi: 10.1007/s002770050523.
6
Bone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide.砷剂治疗急性早幼粒细胞白血病患者的骨髓发现。
Am J Clin Pathol. 2019 Oct 7;152(5):675-685. doi: 10.1093/ajcp/aqz087.
7
Fast pH-Driven Solubilization Method of Realgar (AsS) to Reduce the Toxicity of Arsenic [As(III)] for Medicinal Purposes.用于药用目的的雄黄（AsS）快速pH驱动增溶方法以降低砷[As(III)]的毒性
Adv Sci (Weinh). 2025 Aug;12(29):e2502740. doi: 10.1002/advs.202502740. Epub 2025 Apr 24.
8
IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells.IL1RAP 特异性 T 细胞衔接器耗竭急性髓系白血病干细胞。
J Hematol Oncol. 2024 Aug 14;17(1):67. doi: 10.1186/s13045-024-01586-x.
9
Arsenic Primes Human Bone Marrow CD34+ Cells for Erythroid Differentiation.砷促使人类骨髓CD34+细胞向红系分化。
Bioinorg Chem Appl. 2015;2015:751013. doi: 10.1155/2015/751013. Epub 2015 Jun 11.
10
Atypical blasts and bone marrow necrosis associated with near-triploid relapse of acute promyelocytic leukemia after arsenic trioxide treatment.三氧化二砷治疗后急性早幼粒细胞白血病近三倍体复发相关的非典型原始细胞和骨髓坏死
Hum Pathol. 2002 Aug;33(8):849-51. doi: 10.1053/hupa.2002.125770.

本文引用的文献

1
MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic Leukemia.急性白血病中的微小残留病：从急性早幼粒细胞白血病中汲取的经验教训。
Cancers (Basel). 2024 Sep 20;16(18):3208. doi: 10.3390/cancers16183208.
2
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of .吉特替尼作为伴有. 内部串联重复突变的 AML 移植后维持治疗。
J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12.
3
Burden of AML, 1990-2019: Estimates From the Global Burden of Disease Study.1990 - 2019年急性髓系白血病负担：全球疾病负担研究的估计数
JCO Glob Oncol. 2023 Sep;9:e2300229. doi: 10.1200/GO.23.00229.
4
The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away.维甲酸在癌症治疗中的前景：并非日薄西山，亦非渐趋式微。
Cancers (Basel). 2023 Jul 8;15(14):3535. doi: 10.3390/cancers15143535.
5
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.代谢适应导致三氧化二砷治疗急性早幼粒细胞白血病耐药。
Blood Adv. 2022 Jan 25;6(2):652-663. doi: 10.1182/bloodadvances.2021005300.
6
A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML.一项关于IRX195183（一种RARα选择性CYP26抗性类视黄醇）用于复发或难治性急性髓系白血病患者的1期研究。
Front Oncol. 2020 Oct 23;10:587062. doi: 10.3389/fonc.2020.587062. eCollection 2020.
7
All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.全反式维甲酸与恩西地平联合诱导 IDH2 突变型急性髓系白血病细胞分化。
Yonsei Med J. 2020 Sep;61(9):762-773. doi: 10.3349/ymj.2020.61.9.762.
8
Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids.使用对细胞色素P450 26（CYP26）耐药的类视黄醇克服微环境介导的全反式维甲酸（ATRA）保护作用。
Leukemia. 2020 Nov;34(11):3077-3081. doi: 10.1038/s41375-020-0790-4. Epub 2020 Mar 9.
9
Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment.白血病骨髓微环境中药物代谢酶的调控。
J Cell Mol Med. 2019 Jun;23(6):4111-4117. doi: 10.1111/jcmm.14298. Epub 2019 Mar 28.
10
Retinoic acid, CYP26, and drug resistance in the stem cell niche.维甲酸、细胞色素P450 26家族（CYP26）与干细胞微环境中的耐药性
Exp Hematol. 2017 Oct;54:17-25. doi: 10.1016/j.exphem.2017.07.004. Epub 2017 Jul 25.